Article (Scientific journals)
Le medicament du mois. Etoricoxib (Arcoxia)
Leclercq, P.; Malaise, Michel
2004In Revue Médicale de Liège, 59 (5), p. 345-349
Peer reviewed
 

Files


Full Text
Malaise_2004_RevMedLiege_345-349.pdf
Publisher postprint (514.68 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-Inflammatory Agents, Non-Steroidal; Isoenzymes; Membrane Proteins; Pyridines; Sulfones; Cyclooxygenase 2; etoricoxib; Prostaglandin-Endoperoxide Synthases
Abstract :
[en] Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.
Disciplines :
Rheumatology
Author, co-author :
Leclercq, P.
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Language :
French
Title :
Le medicament du mois. Etoricoxib (Arcoxia)
Alternative titles :
[en] Etoricoxib (Arcoxia)
Publication date :
2004
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Hopital de Baviere, Liège, Belgium
Volume :
59
Issue :
5
Pages :
345-349
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 19 September 2010

Statistics


Number of views
304 (5 by ULiège)
Number of downloads
890 (4 by ULiège)

Scopus citations®
 
21
Scopus citations®
without self-citations
21

Bibliography


Similar publications



Contact ORBi